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Summary
Idiopathic hypercalciuria (HC) occurs in about 50% of patients
with nephrolithiasis and is often associated with the fasting
HC. While increasing the risk for stone formation HC may in-
volve mineral metabolism and bone turnover, as a conse-
quence of sustained negative calcium balance, despite in-
creased intestinal absorption of calcium. Therapeutic options
take account of this. Apart from dietary management, which is
treated elsewhere, drugs so far used in HC patients include:
thiazides, alkali, bisphosphonates, neutral potassium phos-
phate. Issues concerning mechanisms and treatment of some
genetic HC are also discussed in this review.
Thiazides alone or in association with amiloride, reduce calcium
excretion, revert external balance and protect bone from dem-
ineralisation. They act by increasing calcium reabsorption at the
cortical segment of the distal tubule. Over long-term there is net
retention of calcium, which results in a favourable impact on
bone, as suggested by a number of epidemiology studies. Thi-
azides was also shown to exert direct effects on bone, by acting
on osteoblast function. These studies strongly support thi-
azides use when negative calcium balance and enhanced bone
resorption are suspected. Hypertensive patients with HC are al-
so eligible, but no limitation to their extensive use exists. 
Alkaline potassium citrate has a dual effect on HC: citrate an-
ion strongly binds to calcium; alkalinisation expectedly re-
duces bone resorption. Thus both ionised and total calcium
excretion are decreased by citrate. The same effects are
shared by other alkaline compounds, such as potassium bi-
carbonate, which improved calcium balance, reduced bone re-
sorption and increased bone formation in postmenopausal
women. Potassium citrate was shown to induce similar effects
in healthy menopausal women over a short-term course. 
The well known effect of bisphosphonates on bone resorption
will theoretically lower calcium excretion. Alendronate, pre-
vented HC induced by prolonged bed-rest. Genetic hypercalci-
uric rats reduced calcium excretion on alendronate adminis-
tration. Alendronate 10 mg/daily reduced both fasting and 24-
hr calcium excretion in patients with fasting HC over a two-
year follow-up. 
Renal phosphate leak HC has been treated with neutral potas-
sium phosphate. Daily dosages of 40 mmoles decreased urine
calcium, by acting on both intestinal absorption and bone re-
sorption, an effect consistent with a contribution of bone to
the phosphate-depletion induced HC. 
Genetic disorders associated with HC involve mutations of
candidate genes including chloride channel 5 (CLCN-5), the
calcium sensing receptor (CaR) and the paracellin-1 (PCLN-1).
Studies performed in these subsets not only contributed to
clarify mechanisms of the disease, but also help to under-
stand the pathophysiology of HC. Treatment of these genetic
HC was addressed by recent reports, which used thiazides in
Dent's syndrome, CaR and PCLN-1 mutations, vitamin D and
synthetic human PTH in CaR, with encouraging results. 
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bisphosphonates, potassium phosphate.
Introduction
Idiopathic hypercalciuria is the most frequent metabolic abnor-
mality since up to 40 to 60% of patients with nephrolithiasis are
hypercalciuric (1,2-5). Fasting hypercalciuria, accompanies id-
iopathic hypercalciuria in up to 50% of the patients (6). It is
widely agreed that high calcium excretion may be causative for
stone disease, because the higher calcium concentration, the
higher the state of saturation with the calcium forming salts (7).
However, a more general involvement of mineral metabolism,
and in particular bone turnover, comes from the fact that virtu-
ally all of these patients tend to develop a negative external
balance of calcium, because renal loss overtakes net calcium
absorption at the intestine (8). 
The mechanisms of hypercalciuria are complex and not fully
clarified as yet, and this issue is the object of another article in
the Journal. Anyway, a better understanding of the pathogene-
sis of hypercalciuria represents the basis of the different thera-
peutic options so far pursued, which will be the object of the
present review. These are listed in Table I. The points concern-
ing the dependence of calcium excretion on dietary factors will
be omitted, being treated elsewhere in this issue. 
Table I - Therapeutic options in primary hypercalciuria.
Diet and Fluid intake
Thiazides 
Alkali 
Bisphosphonates
Neutral Potassium Phosphate 
Recent issues
Thiazide diuretics
The drugs of this class have been widely used in patients with
calcium nephrolithiasis, more so in those presenting with idio-
pathic hypercalciuria (9-11). Hydrochlorothiazide, chlortalidone
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(10) or trichlormethiazide, alone or in association with amiloride
(11), induce a significant reduction of calcium excretion, revert
external balance of calcium to positive (12), and protect bone
from demineralisation (13-15). Thiazides are able to reduce
calcium excretion by acting at the cortical segment of the distal
tubule, where they increase calcium reabsorption. This mecha-
nism is thought to ensue from contraction of extra-cellular fluids
induced by these drugs (16). Prostaglandin E2, which is likely
involved in the pathogenesis of hypercalciuria, was suggested
to be inhibited by thiazides (17). It has also been hypothesised
that, over long-term therapy, they reduce both intestinal ab-
sorption (12,18) and bone resorption of calcium (19). Zerwekh
et al. found that 50 mg of hydrochlorothiazide twice daily re-
duced fractional intestinal absorption of calcium from 0.68 to
0.56 in patients with renal leak hypercalciuria, but not in those
with absorptive hypercalciuria, and this effect was attributed to
a reduction of serum levels of calcitriol (18). Reduction of calci-
um intestinal absorption was also observed by Coe et al. in 7
patients with severe hypercalciuria after 3 and 6 months of ei-
ther chlortalidone or trichlormethiazide: despite this, calcium re-
tention improved because calcium loss decreased even more.
No changes were seen in calcitriol and parathormone serum
concentrations (12). Favus et al. carried out an experimental
study on rats in which secondary hyperparathyroidism was in-
duced by a low-calcium diet (20). They found that thiazides
prevented the increase in PTH induced by low-calcium diet but
not the increase in calcitriol nor intestinal calcium transport,
and the drug caused no change in rats fed normal chow. Fur-
thermore, in rats given exogenous calcitriol to stimulate intesti-
nal calcium absorption, thiazides greatly reduced urine calcium
excretion but did not alter intestinal calcium absorption (20).
The issue of calcium absorption and thiazides is important for
the potential effect on intestinal absorption of oxalate, in that in-
testinal transport of the former influences the latter (21,22).
Earlier reports of the effects of thiazides found a decrease in
oxalate excretion (10), whereas others failed to confirm it (23).
This topic has not so far been studied in more depth. 
The positive calcium balance induced by long-term therapy
with thiazides may have a favourable impact on bone. A num-
ber of epidemiology studies have addressed this issue, and
found that the risk of hip fractures reduced by 20% and 50%
over more than 2.5 and 6 years of therapy, respectively (13,
14). A rapid recovery of bone mass occurred in osteoporotic
hypercalciuric men given thiazides (15). In a meta-analysis on
13 observational studies in which 29,600 subjects had ex-
tractable data on thiazides and fracture occurrence, current
thiazide users of long duration were protected against hip frac-
ture with a 20% reduction in risk, whereas short duration use
did not (24). In a large survey conducted by U.S. on 83,728
women aged 36-61 at baseline and followed for 10 years,
there was 22% reduction in the risk of forearm fractures
among current thiazide users, reaching 37% among women
who had been using thiazides for 8 or more years. For hip
fractures, thiazide use yielded a 31% reduction in the relative
risk (25). In a recent 2-year prospective follow-up conducted
on 138 women given hydrochlorothiazide 50 mg per day, urine
calcium excretion and indices of bone turnover decreased in
the thiazide group. DEXA bone mineral density improved in to-
tal body, mid- and ultradistal forearm and legs, but no effect
was seen in the lumbar spine or femoral neck, leading Authors
to conclude that thiazides are not an appropriate monotherapy
for treating osteoporosis (26). In a prospective population-
based cohort study, on 7,891 individuals 55 years of age, cur-
rent use of thiazides for more than 1 year was associated with
a lower risk for hip fracture, but this protective effect disap-
peared within 4 months after use was discontinued (27). The
mechanisms of the beneficial effects of thiazides on bone may
be not merely related to their ability to reduce urinary calcium,
and direct effects on bone resorption were postulated. This ef-
fect is partly due to a reduction in PGE2 synthesis (17). Thi-
azides have specific effects on osteoblasts, because they re-
duce serum osteocalcin. I  vitro studies on human osteoblast-
like cell line showed hydrochlorothiazide dose-dependently in-
hibited 1,25-dihydroxyvitamin D3-induced osteocalcin release
and mRNA expression, independently of VDR or extracellular
C a2 + levels, and TNF-a induced production con macrophage
CSF as well. This may explain its preventive role in bone loss
rate (28,29).
The majority of the aforementioned studies support indications
to thiazide use especially in the setting of hypercalciuria asso-
ciated with negative calcium balance and enhanced bone re-
sorption. Anyway, the former limitation of thiazides use to renal
hypercalciuria was subsequently extended to any type of hy-
percalciuria, in both adults (30,10-13) and children (31). The
favourable effects on stone recurrences obtained by using
higher dosages, i.e. hydrochlorothiazide 50 mg twice daily (10)
or chlortalidone 50 mg/day (32), were also confirmed with low-
e  doses and even in the absence of a marked reduction of cal-
cium excretion (1,33). The rationale for the use of lower
dosages is to reduce the impact of side-effects, including hy-
potension, potassium wasting and hypopotassiemia, increase
of plasma bicarbonate (and urate), and a consequent decrease
in citrate excretion. The latter event may be as important as to
offset the benefits related to the reduction of calcium excretion.
It is agreed that some of these side-effects can be lessened by
giving thiazides with amiloride (11), and by supplementing
potassium citrate in the presence of hypocitraturia (34). Hyper-
calciuric patients presenting with hypertension may be espe-
cially eligible for thiazides (35). 
Potassium citrate
Citrate supplementation, as alkaline potassium salt, was for-
merly introduced in the treatment of distal renal tubular acido-
sis (36) and subsequently extended to idiopathic hypocitraturic
calcium nephrolithiasis (37). Regardless of the accompanying
cation (sodium, potassium, magnesium) citrate salts exhibit di-
rect effects on calcium excretion, acting by two distinct mecha-
nisms: first, citrate anion is a strong ligand of calcium, and this
will result in a decrease in free ionised calcium concentration
(38); second, alkalinisation is expected to reduce bone resorp-
tion (39), thereby decreasing total calcium excretion. 
The principal effect of citrate on calcium excretion is due to its
bility to bind calcium, so that the calcium-citrate soluble com-
pl x accounts for by about 10 to 40% of total urinary calcium
(Figure 1). Therefore, an increase in urinary citrate will result in
a decrease in the fraction of free-ionised calcium, which is the
48 Clinical Cases in Mineral and Bone Metabolism 2004; 1(1): 47-52
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F i g u r e1 - Dependence of free ionised calcium on citrate in urine
specimens at two different total calcium concentrations.
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species thermodynamically important for the saturation of calci-
um forming salts (38).
The effect of potassium citrate upon the skeleton is shared by
other alkaline salts, such as potassium bicarbonate. In fact, in
postmenopausal women, the oral administration of potassium
bicarbonate, at a dose sufficient to neutralise endogenous acid,
improved calcium balance, by reducing calcium excretion,
through a reduction of bone resorption and an increase in the
rate of bone formation (40). In a prospective short-term study,
alkaline mineral water induced a significant reduction in the
biochemical markers of bone resorption (9). There also are re-
cent reports of a specific effect of potassium intake on calcium
excretion, because it has been found that potassium deficiency
increases, whereas potassium supplementation as either cit-
rate or bicarbonate or chloride salts, decreases calcium excre-
tion (41). Potassium citrate, given to healthy menopausal
women decreased net acid excretion and concurrently de-
creased markers of bone resorption (Figure 2). Percent varia-
tions of urine citrate were inversely related to those of de-
oxypyridinolines and hydroxyproline, whereas calcium excre-
tion exhibited only minor decreases (42). 
Bisphosphonates
Bisphosphonates are widely used to prevent osteoporosis and,
among these, alendronate and risedronate, exhibit a
favourable efficacy/safety profile over long-term use (43-45).
Theoretically, if increased bone resorption partly explained id-
iopathic hypercalciuria, it follows that drugs capable of reduc-
ing the rate of bone turnover should also have some effect on
calcium excretion. Alendronate, 20 mg daily, had been shown
to prevent hypercalciuria and the calcium-stone forming
propensity induced by prolonged bed-rest (46). Independently
of immobilization, genetic hypercalciuric rats reduced both cal-
ium excretion and urine saturation with calcium salts upon al-
endronate administration (47). The effects of bisphosphonates
on calcium excretion was studied in the phosphate depletion
induced hypercalciuria, which is referred to as being caused by
increased efflux of calcium from bone. Phosphate depleted rats
developed hypophosphatemia, hypercalcemia and hypercalci-
ria, but failed to respond to pamidronate, despite an improved
bone histology (48). 
Recently we have reported similar results in patients with fast-
ing hypercalciuria who had been given alendronate 10 mg/daily
and re-studied after a three-month course. There was a signifi-
cant decrease in both fasting and 24-hour calcium excretion
and, consequently, a 43% reduction in urine saturation with
calcium oxalate (49). These changes were obtained in the face
of normal levels of plasma calcium and only minor and tran-
sient increases in serum PTH, and maintained over a two-year
follow-up (Figure 3). From these results bisphosphonates ap-
pear as promising new tools in the management of hypercalci-
uria, namely in the fasting hypercalciuria or in patients with bio-
chemical (and clinical) evidence of increased bone resorption. 
Neutral potassium phosphate
An association between hypercalciuria and renal phosphate
leak was first described by Bordier et al. (50), who speculated
that a primary defect of phosphate reabsorption at the proximal
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F i g u r e2 - Effetcs of a three-month course of potassium citrate on
bone metabolism and calcium excretion in post-menopausal
women. Treated women (panel A) are compared to untreated ones
(panel B) (**p<0.001 vs baseline; **p<0.01 vs baseline). 
A
B
F i g u r e3 - Long-term effects of Alendronate, 10 mg daily, on bone
resorption (lower panel) and calcium excretion (upper panel) in hy-
percalciuric patients. (* p<0.05; ** p<0.01 vs basal values).
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renal tubule could be responsible for hypophosphatemia, acti-
vation of the renal 1a -25(OH)2 vitamin D3 hydroxylase and par-
tial inhibition of PTH secretion. The associated hypercalciuria
would ensue from both increased intestinal absorption and de-
creased tubular resorption of calcium. That this subtype of hy-
percalciuria can be of clinical significance was confirmed by a
recent report in which 19% of 207 stone formers had a TmPi of
less than 0.63 mmol versus 5% of controls; daily calcium ex-
cretion was higher in stone formers, more so if they had re-
duced TmPi (51). It was also suggested that this hypothetical
tubular defect could involve the type IIa Na+-phosphate co-
transporter through mutations of the encoding gene Npt2. In
fact, knock-out mice for the Npt2 gene [Npt2(–/–)] exhibited in-
creased urinary Pi excretion, hypophosphatemia, elevation in
1 , 2 5 - ( O H )2 vitamin D, hypercalcemia, hypercalciuria and low
PTH (52). Partially deficient mice [Npt2(+/–)] had similar
though milder changes. It was suggested these features be
typical of patients with hereditary hypophosphatemic rickets
with hypercalciuria (HHRH), and that patients with phosphate
leak hypercalciuria could have heterozigous mutations of the
Npt2 gene (51,53). However, others have denied that Npt2 mu-
tations could be responsible for both diseases (54,55). 
Phosphate supplementation, as neutral slow-release potassi-
um phosphate, was given to patients with absorptive hypercal-
ciuria. In a short-term study daily dosages corresponding to 40
mmoles of phosphate and 63.5 mmoles of potassium de-
creased 24-hr and fasting urinary calcium by 40% and 43%, re-
spectively (56). These marked changes were not simply attrib-
utable to a decrease in intestinal absorption of calcium, which
only fell by 6%, but were associated to a clear-cut decrease in
bone resorption, as suggested by the significant decline in
markers of bone turn over. These effects are consistent with
the aforementioned contribution of bone resorption to the phos-
phate-depletion induced hypercalciuria (48). The efficacy of
phosphate supplementation to restore mineral metabolism are
still debatable since, in the presence of renal leak, an increase
in phosphate disposal could result in phosphaturia. In mice
Npt2 (–/–) phosphate supplementation did not prevent hyper-
calciuria and renal calcification, unless associated to 1a-hy-
droxylase gene ablation (57). If this also applied to humans,
treatment of phosphate leak should not only include phosphate
supplies but also inhibition of calcitriol synthesis.
Recent issues on treatment of genetic hypercalciuria
The amazing advances in molecular genetics have also in-
volved hypercalciuria, and at least three candidate genes were
shown to arbour mutations leading to altered calcium excretion.
The chloride channel 5 (ClC-5), the calcium sensing receptor
and the paracellin-1 are proteins encoded by corresponding
genes, whose mutations causing either loss or gain of function,
lead to hypercalciuric syndromes (Table II). Transfection or
gene-disruption studies with these genes not only contribute to
clarify mechanisms of the underlying diseases, but also help to
understand the pathophysiology of idiopathic hypercalciurias. 
R cent reports have addressed the issue of treatment of ge-
netic hypercalciurias, namely, in the course of Dent's syndrome
and familial hypocalcemic hypercalciuria. 
The mechanism leading to hypercalciuria in Dent's syndromes
is as yet not fully elucidated, in that both intestinal hyperab-
sorption and renal leak could contribute. Chlorthalidone, but
not amiloride, was shown to reduce both calcium excretion and
calcium oxalate and calcium phosphate supersaturation in
Dent's syndrome, yielding similar results as in patients with id-
iopathic hypercalciuria (58). These results led authors to con-
clude that the hypocalciuric response to thiazides indicates that
inactivation of the ClC-5 does not impair calcium transport in
the distal convoluted tubule and that thiazides should be effec-
tive in reducing the risk of kidney stone recurrence in these pa-
tients.
Different approaches were tried in patients with CaR mutations
with gain of function. These patients may present with hypocal-
cemia of various severity, some of them presenting with major
clinical signs of hypocalcemia. The classical treatment with ac-
tive vitamin D derivatives, while relieving hypocalcemic symp-
toms, induced significant increases in calcium excretion with an
attendant risk of nephrocalcinosis (59). More recently, synthetic
human PTH-(1-34) was shown to provide a safe and effective
alternative to calcitriol therapy, able to maintain normal serum
calcium levels without hypercalciuria (60). Similar encouraging
results have been reported in two such patients by using hy-
drochlorothiazide (1 mg/kg), which reduced urinary calcium ex-
cretion and maintained serum calcium concentrations near the
lower limit of normal, allowing the vitamin D doses to be re-
duced, while alleviating symptoms (61).
Finally, magnesium salts and thiazides were used to treat pa-
tients with FHHNC (see Table II) caused by paracellin-1 muta-
tions. While being of some efficacy to correct biochemical
changes, treatment did not prevent, however, progression to
chronic renal failure, which is a feature of this disease (62). 
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